Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.
Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells Antivascular therapies are currently intensively studied approaches in clinical oncology. Low molecular weight vascular disrupting agents (VDA) aim to cause rapid and selective shutdown of the established tumor vasculature, leading to massive cancer cell death in the central areas of tumor [1]. However, a common feature of VDA that is poorly understood is the sparing of a relatively intact viable rim at the periphery of the tumor. This viable rim leads to rapid regrowth of tumors and consequently poor responses to VDA when given as a single agent [1]. Combination therapy with chemo-or radiotherapy has produced promising responses in preclinical models and is currently being evaluated in early clinical developments.